Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer

Keisuke Uehara, Seiji Ishiguro, Eiji Sakamoto, Atsuyuki Maeda, Masaya Inoue, Yuichiro Tojima, Satoshi Kobayashi, Naoki Omiya, Naoki Ishizuka, Akimasa Nakao, Hidemi Goto, Masato Nagino

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study.

Original languageEnglish
Article numberhyr084
Pages (from-to)1041-1044
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number8
DOIs
Publication statusPublished - 01-08-2011
Externally publishedYes

Fingerprint

Rectal Neoplasms
Drug Therapy
Survival
Japan
Radiotherapy
Therapeutics
Recurrence
Chemoradiotherapy
Antineoplastic Agents
Disease-Free Survival
XELOX
Bevacizumab
Neoplasm Metastasis
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Uehara, K., Ishiguro, S., Sakamoto, E., Maeda, A., Inoue, M., Tojima, Y., ... Nagino, M. (2011). Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer. Japanese Journal of Clinical Oncology, 41(8), 1041-1044. [hyr084]. https://doi.org/10.1093/jjco/hyr084
Uehara, Keisuke ; Ishiguro, Seiji ; Sakamoto, Eiji ; Maeda, Atsuyuki ; Inoue, Masaya ; Tojima, Yuichiro ; Kobayashi, Satoshi ; Omiya, Naoki ; Ishizuka, Naoki ; Nakao, Akimasa ; Goto, Hidemi ; Nagino, Masato. / Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer. In: Japanese Journal of Clinical Oncology. 2011 ; Vol. 41, No. 8. pp. 1041-1044.
@article{b34fb0dd49ca4e4896da364a6bf20853,
title = "Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer",
abstract = "In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study.",
author = "Keisuke Uehara and Seiji Ishiguro and Eiji Sakamoto and Atsuyuki Maeda and Masaya Inoue and Yuichiro Tojima and Satoshi Kobayashi and Naoki Omiya and Naoki Ishizuka and Akimasa Nakao and Hidemi Goto and Masato Nagino",
year = "2011",
month = "8",
day = "1",
doi = "10.1093/jjco/hyr084",
language = "English",
volume = "41",
pages = "1041--1044",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

Uehara, K, Ishiguro, S, Sakamoto, E, Maeda, A, Inoue, M, Tojima, Y, Kobayashi, S, Omiya, N, Ishizuka, N, Nakao, A, Goto, H & Nagino, M 2011, 'Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer', Japanese Journal of Clinical Oncology, vol. 41, no. 8, hyr084, pp. 1041-1044. https://doi.org/10.1093/jjco/hyr084

Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer. / Uehara, Keisuke; Ishiguro, Seiji; Sakamoto, Eiji; Maeda, Atsuyuki; Inoue, Masaya; Tojima, Yuichiro; Kobayashi, Satoshi; Omiya, Naoki; Ishizuka, Naoki; Nakao, Akimasa; Goto, Hidemi; Nagino, Masato.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 8, hyr084, 01.08.2011, p. 1041-1044.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer

AU - Uehara, Keisuke

AU - Ishiguro, Seiji

AU - Sakamoto, Eiji

AU - Maeda, Atsuyuki

AU - Inoue, Masaya

AU - Tojima, Yuichiro

AU - Kobayashi, Satoshi

AU - Omiya, Naoki

AU - Ishizuka, Naoki

AU - Nakao, Akimasa

AU - Goto, Hidemi

AU - Nagino, Masato

PY - 2011/8/1

Y1 - 2011/8/1

N2 - In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study.

AB - In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study.

UR - http://www.scopus.com/inward/record.url?scp=79961044483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961044483&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyr084

DO - 10.1093/jjco/hyr084

M3 - Article

C2 - 21803876

AN - SCOPUS:79961044483

VL - 41

SP - 1041

EP - 1044

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

M1 - hyr084

ER -